加载中
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
前收盘价
US$2.67
−US$0.03 · -1.11%
盘中时间采用ET。市场数据可能有所延迟。
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
日内区间
当前US$2.67
52周区间
当前US$2.67
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
31
偏贵
情绪
54
多空交织
风险
59
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
日内区间
当前US$2.67
52周区间
当前US$2.67
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.54亿 USD | 7327.8万 USD | 2767万 USD | 2425万 USD | 3839.6万 USD |
| 销售、一般及管理费用 | 1827.3万 USD | 1761.2万 USD | 1408.8万 USD | 1227.6万 USD | 1206.9万 USD |
| 营业费用 | 1.72亿 USD | 9089万 USD | 4175.8万 USD | 3652.6万 USD | 5046.5万 USD |
| 折旧和摊销 | 35万 USD | 31.8万 USD | 31.1万 USD | 31.8万 USD | 32.6万 USD |
| 营业利润 | −1.72亿 USD | −9089万 USD | −4175.8万 USD | −3652.6万 USD | −5046.5万 USD |
| 净利润 | −1.66亿 USD | −8060.4万 USD | −3694.9万 USD | −3535.5万 USD | −5063.6万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.00
上涨空间 199.63%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2020年5月29日 | 1:12 | — | — |
已生效 2020年5月29日
1:12
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI842.86万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM475.86万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF267.2万0.00%954亿 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM265.29万0.04%64.1亿 USD0.28%US$45.46+0.46%
iShares Russell 2000 Growth ETFIWO168.14万0.01%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO146.47万0.01%180亿 USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS122.26万0.00%338.69亿 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB100.55万0.01%108.2亿 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
